Company profile
XOMA Royalty Corp.
NASDAQ: XOMA · Healthcare · Biotechnology
#629 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
75B+FH 81DQ 72GM 66SS 69
v0.1 · 65/100 weight · provisional
↑ operating margin, net margin · ↓ workforce scale, growth stability
Methodology →Revenue TTM
$36.2M
Rev growth YoY (TTM)
-3.3%
Net income (FY)
$31.7M
Employees
14
as of 2026-08-11
Market cap
$503.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$10.3M$10.3M2025
Net income$31.7M$31.7M2025
Operating income$11.4M$11.4M2025
Total assets$272.7M$272.7M2025
Liabilities$168.7M$168.7M2025
Equity$83.9M$83.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is XOMA Royalty Corp.’s revenue?
XOMA Royalty Corp. booked $10.3M in FY2025 revenue, growing 56% year over year — faster than most Healthcare companies we track, at a 306.4% net margin.
Peers · Healthcare
Ventura Cannabis & Wellness Corporation——PrimeMD Inc——HealthWarehouse.com, Inc.——TScan Therapeutics, Inc.39DAlpha Cognition Inc39DKhiron Life Sciences Corp.——Neighbors
Alameda →Key facts
CEOOwen Hughes Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersEmeryVille, CA
ExchangeNASDAQ: XOMA
Employees14
IPO date1986-06-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.